Phase I, Open-Label Study of Autologous Mutant KRAS and ILT4-Redirected T-cell Receptor Cells (TCR1188-ABC)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT07594067

Title field or adapter rule

{'original_value': 'Phase I, Open-Label Study of Autologous Mutant KRAS and ILT4-Redirected T-cell Receptor Cells (TCR1188-ABC)', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:23.426712+00:00

Published At

2026-10-14T00:00:00+00:00

Record Updated At

2026-10-14

Source Retrieved At

2026-10-31T22:17:52.415050+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Cholangiocarcinoma", "Colorectal Cancer", "Non-Small Cell Lung Cancer", "Pancreatic Adenocarcinoma"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-14", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT07594067"

protocolSection.identificationModule.officialTitle

"Phase I, Open-Label Study of Autologous Mutant KRAS and ILT4-Redirected T-cell Receptor Cells (TCR1188-ABC)"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["PHASE1"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Cholangiocarcinoma (protocolSection.conditionsModule.conditions)
• Colorectal Cancer (protocolSection.conditionsModule.conditions)
• Non-Small Cell Lung Cancer (protocolSection.conditionsModule.conditions)
• Pancreatic Adenocarcinoma (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Dose level -1', 'Dose level 1', 'Dose level 2', 'Dose level 3'], 'description': 'TCR1188 modified, base-edited autologous CD4+ and CD8+ T cells expressing TCR1188 and a scFv fragment specific to ILT4 (LILRB2) as a Single infusion on Day 0', 'name': 'TCR1188-ABC cells', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Dose level -1', 'Dose level 1', 'Dose level 2', 'Dose level 3'], 'description': 'Fludarabine: 30 mg/m2/day x 4 days (Day -7 to -4) Cyclophosphamide: 600mg/m2/day x 3 days (Day -7 to -5)', 'name': 'Fludarabine + Cyclophosphamide combination', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Dose level -1', 'Dose level 1', 'Dose level 2', 'Dose level 3'], 'description': 'Single administration of 8mg/kg on Day 2 (+3d)', 'name': 'Tocilizumab', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• Fludarabine + Cyclophosphamide combination (protocolSection.armsInterventionsModule.interventions[].name)
• Tocilizumab (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.